---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-067509"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:51:56.329022+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Artiva Biotherapeutics appoints Thad Huston as CFO effective Feb 18, 2026

## Summary
- Thad Huston appointed CFO, principal financial and accounting officer, effective Feb 18, 2026.
- Salary $540,000; discretionary annual cash bonus target of 40% of base salary.
- Inducement award of 220,000 RSUs vesting 25% Feb 15, 2027, then quarterly over three years.
- Severance: 9 months base salary (non-CIC) or 12 months + full target bonus (CIC), plus COBRA and accelerated vesting.
- Huston previously CFO/COO at Galapagos NV and held senior roles at Kite Pharma, LivaNova, and Johnson & Johnson.

## SEC filing metadata
- accession: 0001193125-26-067509
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312526067509/0001193125-26-067509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312526067509/artv-20250128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-067509
- JSON: https://secwatch.observer/filing/0001193125-26-067509.json
- Plain text: https://secwatch.observer/filing/0001193125-26-067509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.